eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose dexamethasone (BLLD) for induction, in patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
  5. Additional Topic(s)
    Antineoplastic combined chemotherapy protocols
  6. Resource Description
    RATIONALE: It is not yet known whether lenalidomide and dexamethasone is more effective with or without bortezomib in treating multiple myeloma. PURPOSE: This randomized phase III trial is studying giving lenalidomide and dexamethasone together with bortezomib to see how well it works compared to dexamethasone and lenalidomide alone in treating patients with previously untreated multiple myeloma.
  7. Contact
    Berenberg, Jeffrey
  8. PI
    Berenberg, Jeffrey
  9. Topic
    multiple myeloma
  10. Study Population
    Males and females age 18 and older with newly diagnosed multiple myeloma (MM).
  11. Website(s)
  12. Funded by
  13. Phase
    Phase 3 clinical trial
  14. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016